

# Autism - Pipeline Review, H1 2020

<https://marketpublishers.com/r/A5DD2D043B9EN.html>

Date: January 2020

Pages: 177

Price: US\$ 2,000.00 (Single User License)

ID: A5DD2D043B9EN

## Abstracts

Autism - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H1 2020, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 20, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Autism - Overview
- Autism - Therapeutics Development
- Autism - Therapeutics Assessment
- Autism - Companies Involved in Therapeutics Development
- Autism - Drug Profiles
- Autism - Dormant Projects
- Autism - Discontinued Products
- Autism - Product Development Milestones
- Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Autism, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Autism - Pipeline by 4D Pharma Plc, H1 2020  
Autism - Pipeline by AgeneBio Inc, H1 2020  
Autism - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020  
Autism - Pipeline by APeT Holding BV, H1 2020  
Autism - Pipeline by AsiaBiome, H1 2020  
Autism - Dormant Projects, H1 2020  
Autism - Dormant Projects, H1 2020 (Contd..1), H1 2020  
Autism - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Autism, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

4D Pharma Plc  
AgeneBio Inc  
AgoneX Biopharmaceuticals Inc  
APeT Holding BV  
AsiaBiome  
Blackthorn Therapeutics Inc  
BrainStorm Cell Therapeutics Inc  
Cennerv Pharma (S) Pte Ltd  
Cox Biosciences LLC  
Curemark LLC  
Cytocom Inc  
Epigen Biosciences Inc  
F. Hoffmann-La Roche Ltd  
GW Pharmaceuticals Plc  
Immuron Ltd  
Insys Therapeutics Inc  
Intra-Cellular Therapies Inc  
Johnson & Johnson  
Neurochlore  
Omeros Corp  
OptiNose US Inc

Ovensa Inc  
Panorama Research Inc  
Park Active Molecules  
RespireRx Pharmaceuticals Inc  
Reviva Pharmaceuticals Inc  
RogCon Inc  
Rugen Therapeutics R&D (Shanghai) Co Ltd  
Scioto Biosciences Inc  
Sengenics International Pte Ltd  
Sosei Heptares  
Stem Cell Medicine Ltd  
Sumitomo Dainippon Pharma Co Ltd  
Zelira Therapeutics Ltd

## I would like to order

Product name: Autism - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/A5DD2D043B9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5DD2D043B9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970